Ischemic Stroke – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of IS comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the total events and prevalence of IS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s IS forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of IS?
- Of all people diagnosed with IS, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts three IS patient populations, including the following:
- Total IS events.
- Total lifetime prevalent cases of IS.
- Diagnosed 12-month prevalent cases of IS.
Note: Coverage may vary by country.
